Dr. Michael McKenzie is Radiation Oncologist at the BC Cancer Agency (BCCA). He has been in practice since 1985 and has extensive experiences in genitourinary oncology, neuro-oncology and palliative oncology.

1. [00:07] Surgical castration: This is a day surgery under local anesthetic which involves removing the testicles. While the idea sounds terrible, the reality of it is fairly simple. Once removed, you cannot put the testicles back in and you will experience life-long low testosterone level.
2. [01:52] Medical androgen deprivation therapy: Luteinizing hormone releasing hormone (LHRH) is administered once a month to every 6 months.
3. [02:31] Luteinizing hormone releasing hormone (LHRH) antagonist: LHRH antagonist is an alternative drug to LHRH. This is administered on a monthly basis.
4. [03:07] Non-steroidal anti-androgen tablets (3+4= Total androgen blockade): Sometimes, LHRH antagonist is given in conjunction with non-steroidal anti-androgen tablets, which are testosterone blockers.
5. [04:43] 5-alpha reductase inhibitors (5-ARIs) – finasteride and dutasteride: These are not usual drugs that treat prostate cancer as they are primarily used to treat the symptoms of age-related benign or non-cancerous enlargement of the prostate.
6. [05:51] Castrate-resistance prostate cancer – Abiraterone and Enzalutamide: If you had androgen deprivation therapy as the primary treatment, over time, the cancer begins to develop some elements of resistance to that therapy, leading to rising in the PSA. There are two new drugs that are available for use in that particular situation. For more info visit [ Ссылка ]

свернуть